Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Global psychotropic drugs market 360° synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Drug type trends
2.1.4 Application trends
2.1.5 Therapeutic class trends
2.1.6 Disease trends
2.1.7 Distribution channel trends
Chapter 3 Psychotropic Drugs Market Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of mental health disorders
3.2.1.2 Rising awareness about mental health
3.2.1.3 Increasing availability of generic psychotropic drugs
3.2.1.4 Rising incidence of substance abuse
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stigma associated with mental illness
3.2.2.2 High cost of psychotropic drugs
3.2.2.3 Side effects associated with consumption of psychotropic drugs
3.3 Growth potential analysis
3.3.1 By drug type
3.3.2 By application
3.3.3 By therapeutic class
3.3.4 By disease
3.3.5 By distribution channel
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company positioning matrix
4.4 Competitive analysis of major market players
4.5 Strategic outlook matrix
4.6 Strategy dashboard, 2022
Chapter 5 Psychotropic Drugs Market Size and Forecast, By Drug type (USD Million)
5.1 Key trends, by drug type
5.2 Aripiprazole
5.3 Brexipiprazole
5.4 Olanzapine
5.5 Peliperidone Palmitate
5.6 Clozapine
5.7 Quetiapine
5.8 Chlorpromazine
5.9 Risperidone
5.10 Paroxetine
5.11 Thioridazine
5.12 Fluvoxamine
5.13 Other drug types
Chapter 6 Psychotropic Drugs Market Size and Forecast, By Application (USD Million)
6.1 Key trends, by application
6.2 Anti-psychotics
6.3 Anti-anxiety
6.4 Mood stabilizers
6.5 Antidepressants
6.6 Stimulants
6.7 Hypnotics
6.8 Antiepileptic drugs
6.9 Other applications
Chapter 7 Psychotropic Drugs Market Size and Forecast, By Therapeutic class (USD Million)
7.1 Key trends, by therapeutic class
7.2 First generation
7.3 Second generation
7.4 Third generation
Chapter 8 Psychotropic Drugs Market Size and Forecast, By Disease (USD Million)
8.1 Key trends, by disease
8.2 Schizophrenia
8.3 Bipolar disorder
8.4 Unipolar depression
8.5 Dementia
8.6 Other diseases
Chapter 9 Psychotropic Drugs Market Size and Forecast, By Distribution channel (USD Million)
9.1 Key trends, by distribution channel
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies
Chapter 10 Psychotropic Drugs Market Size and Forecast, By Region (USD Million)
10.1 Key trends, by region
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Rest of Latin America
10.6 Middle East & Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 Rest of Middle East & Africa
Chapter 11 Company Profiles
11.1 Alkermes
11.2 Eli Lilly and Company
11.3 Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
11.4 Allergan (AbbVie Inc.)
11.5 Pfizer Inc.
11.6 Mylan N.V.
11.7 Novartis AG
11.8 Axsome Therapeutics, Inc.
11.9 Acadia Pharmaceuticals Inc.
11.10 Takeda Pharmaceutical Company Limited
